Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Accolade Revenue

Prestige Biologics had revenue of 3.48B KRW in the quarter ending March 31, 2025, with 444.88% growth. This brings the company's revenue in the last twelve months to 6.71B, up 284.40% year-over-year. In the fiscal year ending June 30, 2024, Prestige Biologics had annual revenue of 2.17B with 24.24% growth.

• Revenue (ttm): 6.71B
• Revenue Growth: +284.40%
• P/S Ratio: 43.16
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 289.63B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2024	2.17B	423.21M	24.24%
Jun 30, 2023	1.75B	1.73B	11,115.88%
Dec 31, 2022	15.57M	-3.21B	-99.52%
Dec 31, 2021	3.23B	-	-
Dec 31, 2020	-	-	-